Experimental lymphoma combo trial halted early – only 5 patients enrolled
NCT ID NCT05498220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new combination of drugs (polatuzumab vedotin plus standard chemotherapy) for patients with diffuse large B-cell lymphoma that came back or didn't improve after initial treatment. The trial aimed to see if this mix could shrink tumors better than standard therapy. However, the study was stopped early after enrolling only 5 people, so we have very little information about how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin combined with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP chemotherapy)
What this could lead to
If successful, this combination could improve response rates for patients whose lymphoma returned after initial treatment, potentially leading to better outcomes before or instead of a stem cell transplant.
What could go wrong
The trial was terminated early with only 5 participants, so results are very limited. The combination may not be more effective than standard therapy and could have significant side effects from the chemotherapy drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States